How Paragraph IV Patent Challenges Speed Up Generic Drug Entry
Paragraph IV certification under the Hatch-Waxman Act lets generic drug makers challenge brand patents early, triggering court battles that can speed up affordable drug access. Learn how it works, why it matters, and who wins.
View more